BBC Virtus Biotech Clinical Trials ETF
Quote as of Aug 26, 2026 20:00 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Previous Close | 55.76 | Day Range | 54.66 – 56.04 |
| 52-Week Range | 22.43 – 56.18 | Volume | 37.34K |
| Avg Volume | 24.62K | AUM | $53.0M (Aug 27, 2026) |
| Expense Ratio | 0.65% | Yield (TTM) | 1.19% |
| NAV | 55.77 | Premium/Discount | -1.11% indicative |
| Inception | Dec 16, 2014 | Holdings | 198 |
| Issuer | Virtus | Exchange | AMEX |
| Category | Biotech | Index Tracked | Not stated in source data |
| CUSIP | 26923G301 | ISIN | US26923G3011 |
| Management | Not stated in source data | ||
About this ETF
This exchange-traded fund (ETF) endeavors to match the capital appreciation and income generation of the LifeSci Biotechnology Clinical Trials Index, disregarding fees and expenses. The underlying index focuses on tracking the financial progress of a carefully chosen group of biotechnology firms engaged in clinical trials. It is important to note that, as of February 27, the fund's official name transitioned from Virtus LifeSci Biotech Clinical Trials ETF to Virtus Biotech Clinical Trials ETF.
Description from the fund data provider · profile as of Aug 27, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | +10.88% | +26.61% | +29.01% | +43.02% | +141.04% | +36.80% | +3.06% | +10.65% | +6.40% |
| Total return | +10.88% | +26.61% | +29.01% | +43.02% | +145.11% | +38.18% | +3.68% | +11.11% | +6.82% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Aug 26, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.65% | Annual cost of a $10,000 investment | $65.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Aug 22, 2026 — portfolio reporting date from the data provider; holdings are not live positions. 132 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | Amylyx Pharmaceuticals Inc | AMLX | 1.65% | 21.30K | $844.9K |
| 2 | First Tracks Biotherapeutics Inc | TRAX | 1.45% | 17.62K | $738.3K |
| 3 | AbCellera Biologics Inc | ABCL | 1.34% | 59.31K | $686.3K |
| 4 | Xencor Inc | XNCR | 1.33% | 25.21K | $680.6K |
| 5 | AtaiBeckley Inc | ATAI | 1.15% | 79.29K | $588.3K |
| 6 | MBX Biosciences Inc | MBX | 1.14% | 8.75K | $580.8K |
| 7 | Monopar Therapeutics Inc | MNPR | 1.13% | 5.20K | $576.6K |
| 8 | Definium Therapeutics Inc | DFTX | 1.12% | 12.56K | $570.1K |
| 9 | 4D Molecular Therapeutics Inc | FDMT | 1.11% | 35.20K | $566.7K |
| 10 | uniQure NV | QURE | 1.08% | 11.27K | $551.1K |
| 11 | SELLAS Life Sciences Group Inc | SLS | 1.04% | 39.70K | $531.9K |
| 12 | ORIC Pharmaceuticals Inc | ORIC | 1.02% | 37.59K | $521.7K |
| 13 | LB Pharmaceuticals Inc | LBRX | 1.01% | 10.94K | $516.5K |
| 14 | REGENXBIO Inc | RGNX | 1.01% | 46.67K | $516.2K |
| 15 | Vor BioPharma Inc | VOR | 0.98% | 21.64K | $499.2K |
| 16 | Zenas Biopharma Inc | ZBIO | 0.97% | 15.70K | $496.3K |
| 17 | Nurix Therapeutics Inc | NRIX | 0.97% | 18.34K | $496.0K |
| 18 | Alto Neuroscience Inc | ANRO | 0.97% | 14.48K | $495.8K |
| 19 | Replimune Group Inc | REPL | 0.96% | 35.00K | $491.8K |
| 20 | Cullinan Therapeutics Inc | CGEM | 0.95% | 22.69K | $485.0K |
| 21 | Immix Biopharma Inc | IMMX | 0.95% | 36.78K | $484.1K |
| 22 | Immunome Inc | IMNM | 0.93% | 16.91K | $474.9K |
| 23 | Apogee Therapeutics Inc | APGE | 0.93% | 3.52K | $474.2K |
| 24 | MeiraGTx Holdings plc | MGTX | 0.92% | 32.41K | $471.2K |
| 25 | Oruka Therapeutics Inc | ORKA | 0.91% | 4.45K | $466.3K |
| 26 | Viridian Therapeutics Inc | VRDN | 0.91% | 19.01K | $465.7K |
| 27 | Climb Bio Inc | CLYM | 0.91% | 27.17K | $462.5K |
| 28 | Assembly Biosciences Inc | ASMB | 0.89% | 13.54K | $453.9K |
| 29 | Damora Therapeutics Inc | DMRA | 0.89% | 14.96K | $453.3K |
| 30 | Achieve Life Sciences Inc | ACHV | 0.88% | 56.31K | $451.6K |
| 31 | Candel Therapeutics Inc | CADL | 0.88% | 36.31K | $448.4K |
| 32 | Dyne Therapeutics Inc | DYN | 0.87% | 17.09K | $443.9K |
| 33 | SpyGlass Pharma Inc | SGP | 0.87% | 16.86K | $442.1K |
| 34 | Design Therapeutics Inc | DSGN | 0.86% | 28.33K | $440.9K |
| 35 | Kymera Therapeutics Inc | KYMR | 0.86% | 3.60K | $438.0K |
| 36 | Sana Biotechnology Inc | SANA | 0.85% | 115.98K | $433.8K |
| 37 | Jade Biosciences Inc | JBIO | 0.84% | 20.26K | $430.1K |
| 38 | Revolution Medicines Inc | RVMD | 0.84% | 2.02K | $427.7K |
| 39 | Praxis Precision Medicines Inc | PRAX | 0.83% | 1.17K | $425.1K |
| 40 | GH Research PLC | GHRS | 0.83% | 14.72K | $422.1K |
| 41 | Ideaya Biosciences Inc | IDYA | 0.82% | 10.72K | $419.5K |
| 42 | Avalo Therapeutics Inc | AVTX | 0.82% | 21.06K | $417.4K |
| 43 | Dianthus Therapeutics Inc | DNTH | 0.81% | 3.79K | $414.7K |
| 44 | Spyre Therapeutics Inc | SYRE | 0.81% | 3.85K | $414.7K |
| 45 | Relay Therapeutics Inc | RLAY | 0.81% | 20.99K | $413.5K |
| 46 | Adlai Nortye Ltd | ANL | 0.81% | 30.12K | $413.2K |
| 47 | Immunovant Inc | IMVT | 0.80% | 9.24K | $410.0K |
| 48 | Palvella Therapeutics Inc | PVLA | 0.80% | 2.86K | $407.2K |
| 49 | Neurogene Inc | NGNE | 0.79% | 10.68K | $405.8K |
| 50 | CG oncology Inc | CGON | 0.79% | 5.22K | $405.0K |
| 51 | Vaxcyte Inc | PCVX | 0.79% | 6.55K | $401.7K |
| 52 | Generate Biomedicines Inc | GENB | 0.79% | 25.11K | $401.4K |
| 53 | Celldex Therapeutics Inc | CLDX | 0.78% | 9.94K | $397.0K |
| 54 | Enliven Therapeutics Inc | ELVN | 0.78% | 6.74K | $397.0K |
| 55 | Solid Biosciences Inc | SLDB | 0.78% | 43.53K | $396.1K |
| 56 | Janux Therapeutics Inc | JANX | 0.78% | 22.92K | $396.1K |
| 57 | Rocket Pharmaceuticals Inc | RCKT | 0.77% | 113.02K | $393.3K |
| 58 | Nektar Therapeutics | NKTR | 0.76% | 5.23K | $390.1K |
| 59 | Scholar Rock Holding Corp | SRRK | 0.76% | 7.04K | $388.7K |
| 60 | Rapport Therapeutics Inc | RAPP | 0.76% | 8.09K | $387.3K |
| 61 | Edgewise Therapeutics Inc | EWTX | 0.76% | 8.93K | $386.4K |
| 62 | Arcus Biosciences Inc | RCUS | 0.76% | 13.06K | $385.5K |
| 63 | Invivyd Inc | IVVD | 0.75% | 403.65K | $383.8K |
| 64 | Erasca Inc | ERAS | 0.74% | 22.12K | $377.8K |
| 65 | Aura Biosciences Inc | AURA | 0.74% | 48.49K | $376.8K |
| 66 | Maze Therapeutics Inc | MAZE | 0.73% | 12.92K | $373.9K |
| 67 | Corvus Pharmaceuticals Inc | CRVS | 0.73% | 26.05K | $373.4K |
| 68 | Biohaven Ltd | BHVN | 0.73% | 27.55K | $372.0K |
| 69 | Viking Therapeutics Inc | VKTX | 0.73% | 10.81K | $371.5K |
| 70 | Arvinas Inc | ARVN | 0.72% | 41.00K | $370.1K |
| 71 | Tectonic Therapeutic Inc | TECX | 0.72% | 10.27K | $370.1K |
| 72 | Oculis Holding AG | OCS | 0.72% | 28.03K | $368.3K |
| 73 | Pharvaris NV | PHVS | 0.72% | 10.12K | $368.2K |
| 74 | Structure Therapeutics Inc | GPCR | 0.72% | 7.24K | $365.8K |
| 75 | Belite Bio Inc | BLTE | 0.71% | 2.25K | $364.4K |
| 76 | BridgeBio Oncology Therapeutics Inc | BBOT | 0.71% | 40.11K | $364.2K |
| 77 | Kodiak Sciences Inc | KOD | 0.71% | 9.12K | $363.5K |
| 78 | Prime Medicine Inc | PRME | 0.71% | 112.00K | $362.9K |
| 79 | Rezolute Inc | RZLT | 0.71% | 77.70K | $362.1K |
| 80 | Compass Therapeutics Inc | CMPX | 0.71% | 153.11K | $361.3K |
| 81 | Disc Medicine Inc | IRON | 0.71% | 4.57K | $360.4K |
| 82 | Lexeo Therapeutics Inc | LXEO | 0.70% | 71.12K | $359.9K |
| 83 | Xenon Pharmaceuticals Inc | XENE | 0.70% | 5.97K | $356.3K |
| 84 | Compass Pathways Plc | CMPS | 0.70% | 25.73K | $355.6K |
| 85 | Lexicon Pharmaceuticals Inc | LXRX | 0.69% | 161.88K | $352.9K |
| 86 | Septerna Inc | SEPN | 0.69% | 8.65K | $352.7K |
| 87 | Altimmune Inc | ALT | 0.69% | 119.09K | $351.3K |
| 88 | Bicara Therapeutics Inc | BCAX | 0.68% | 14.33K | $349.5K |
| 89 | Upstream Bio Inc | UPB | 0.68% | 50.95K | $349.0K |
| 90 | Arbutus Biopharma Corp | ABUS | 0.68% | 72.96K | $348.0K |
| 91 | Allogene Therapeutics Inc | ALLO | 0.67% | 163.59K | $343.5K |
| 92 | Olema Pharmaceuticals Inc | OLMA | 0.67% | 31.49K | $343.2K |
| 93 | Annexon Inc | ANNX | 0.67% | 65.99K | $341.8K |
| 94 | VeraDermics Inc | MANE | 0.67% | 3.23K | $340.7K |
| 95 | Prothena Corp PLC | PRTA | 0.67% | 37.67K | $340.2K |
| 96 | Aktis Oncology Inc | AKTS | 0.67% | 14.17K | $340.2K |
| 97 | CytomX Therapeutics Inc | CTMX | 0.67% | 103.26K | $339.7K |
| 98 | Mineralys Therapeutics Inc | MLYS | 0.66% | 13.16K | $338.8K |
| 99 | Inhibrx Biosciences Inc | INBX | 0.65% | 3.37K | $334.2K |
| 100 | Taysha Gene Therapies Inc | TSHA | 0.65% | 54.43K | $332.6K |
| 101 | Vir Biotechnology Inc | VIR | 0.65% | 36.10K | $332.5K |
| 102 | Cogent Biosciences Inc | COGT | 0.65% | 9.39K | $331.6K |
| 103 | Recursion Pharmaceuticals Inc | RXRX | 0.65% | 98.67K | $329.6K |
| 104 | Cabaletta Bio Inc | CABA | 0.65% | 103.26K | $329.4K |
| 105 | Stoke Therapeutics Inc | STOK | 0.64% | 10.42K | $327.3K |
| 106 | Bicycle Therapeutics PLC | BCYC | 0.64% | 76.74K | $325.4K |
| 107 | Savara Inc | SVRA | 0.64% | 59.09K | $324.4K |
| 108 | Intellia Therapeutics Inc | NTLA | 0.63% | 25.67K | $319.3K |
| 109 | Celcuity Inc | CELC | 0.62% | 3.51K | $317.9K |
| 110 | AnaptysBio Inc | ANAB | 0.62% | 5.54K | $314.2K |
| 111 | Beam Therapeutics Inc | BEAM | 0.60% | 10.71K | $304.0K |
| 112 | ArriVent Biopharma Inc | AVBP | 0.58% | 10.18K | $297.0K |
| 113 | Tyra Biosciences Inc | TYRA | 0.58% | 11.52K | $295.8K |
| 114 | Alumis Inc | ALMS | 0.58% | 12.87K | $294.2K |
| 115 | Newamsterdam Pharma Co NV | NAMS | 0.56% | 10.22K | $284.0K |
| 116 | Vera Therapeutics Inc | VERA | 0.56% | 9.07K | $283.6K |
| 117 | Immatics NV | IMTX | 0.55% | 33.13K | $283.3K |
| 118 | Crescent Biopharma Inc | CBIO | 0.55% | 17.34K | $281.5K |
| 119 | Wave Life Sciences Inc | WVE | 0.54% | 52.95K | $278.0K |
| 120 | Summit Therapeutics Inc | SMMT | 0.54% | 22.18K | $275.8K |
| 121 | ProKidney Corp | PROK | 0.53% | 189.52K | $269.1K |
| 122 | MoonLake Immunotherapeutics | MLTX | 0.52% | 16.63K | $263.9K |
| 123 | Monte Rosa Therapeutics Inc | GLUE | 0.49% | 17.05K | $251.9K |
| 124 | Tango Therapeutics Inc | TNGX | 0.46% | 10.05K | $236.2K |
| 125 | Relmada Therapeutics Inc | RLMD | 0.42% | 46.74K | $216.9K |
| 126 | Evommune Inc | EVMN | 0.42% | 15.67K | $212.7K |
| 127 | BioAge Labs Inc | BIOA | 0.33% | 17.23K | $166.9K |
| 128 | EyePoint Inc | EYPT | 0.25% | 23.85K | $128.8K |
| 129 | MapLight Therapeutics Inc | MPLT | 0.25% | 11.20K | $125.8K |
| 130 | Capricor Therapeutics Inc | CAPR | 0.16% | 12.05K | $82.3K |
| 131 | Cash/Cash equivalents | — | 0.11% | 56.94K | $56.9K |
| 132 | Sionna Therapeutics Inc | SION | 0.09% | 8.65K | $47.8K |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | 1.19% | Paid (last 12 months) | $0.6554 |
| Frequency | Annual | SEC yield | Not provided by our data source — see the issuer page |
| Last ex-date | Dec 22, 2025 | Last payment | $0.6554 (Dec 29, 2025) |
| Growth 1Y | +173.70% | Growth 3Y / 5Y (ann.) | — / — |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Dec 22, 2025 | Dec 22, 2025 | Dec 29, 2025 | $0.6554 |
| Dec 20, 2024 | Dec 20, 2024 | Dec 27, 2024 | $0.2395 |
| Dec 20, 2023 | Dec 21, 2023 | Dec 29, 2023 | $0.0823 |
| Dec 20, 2017 | Dec 21, 2017 | Dec 27, 2017 | $0.3000 |
| Dec 21, 2015 | Dec 23, 2015 | Dec 29, 2015 | $0.1500 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
| Volatility 1Y / 3Y | 36.53% / 37.22% | Sharpe 1Y / 3Y | 4.35 / 1.20 |
| Max drawdown 1Y / 3Y | -15.10% / -54.46% | Sortino 1Y | 7.17 |
| Beta vs S&P 500 (3Y) | 1.21 | Correlation vs S&P 500 (1Y) | 0.387 |
| Downside deviation 1Y | 22.19% | Risk-free rate used | 3.71% (3M T-bill, FRED) |
Computed by ETF Explorer from daily dividend-adjusted closes; volatility and drawdown are annualized/period figures; S&P 500 exposure proxied by SPY. As of Aug 27, 2026. Formulas →
Liquidity
| Volume today | 37.34K | Average volume | 24.62K |
| AUM | $53.0M | Premium/Discount | -1.11% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV — an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Day | $1.7M | +3.34% | $51.3M → $53.0M |
| 1 Week | $557.9K | +1.09% | $51.2M → $53.0M |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source — review them before investing.
Latest News for BBC
No articles mention this fund directly in the last 7 days — showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.